Research
- Grant Applications
- Research News & Reports
- Research Webinar Series
- Clinical Trials
- HD Gene Symposium: 20 Years
- Therapies in Pipeline
- Research Conferences
- Scientific Advisory Board
- Research Pipeline
- Stem Cells
-
HDBuzz
- Minocyline-the end of the road?
- Memantine in HD: dose is everything
- Enroll-HD
- Dimebon
- Active Lifestyle
- How Common is HD?
- PLoS Currents Huntington Disease
- Do HD Brains Develop Differently?
- Connections between Neurodegenerative diseases?
- Huntexil
- Focused Drug Screening
- TRACK-HD
- Meclizine
- HDBuzz on KMO Inhibitor
- HDBUZZ: Digestive Problems in HD
- HDBuzz Re-routing huntingtin inside cells
- HDBuzz Making Babies
- HDBuzz: Caffeine, cannabis and caution
- HDBuzz Cut-and-paste DNA
- Stem cells and HD: past, present and future
- HDBuzz Hidden message in HD gene?
- HDBuzz Protein folding drug helps mice . . . for a while
- Oz Buzz Updates: Day 1
- Oz Buzz Updates: Day 2
- Oz Buzz Updates: Day 3
- Prana Biotech PBT2 Clinical Trial
- Gene Silencing Takes a Targeted Step Forward
- TRACK-HD reveals changes in HD mutation carriers
- HD Buzz: Chinese HD Network
- HDBuzz: Gene Therapy and Stem Cells
- HDBuzz: Bone marrow transplantation in HD
- Double success for huntingtin RNAi gene silencing
- HDBuzz: Mesenchymal stem cells and gene silencing
- HDBuzz: Special 'brain fat' injection helps HD mice
- HDBuzz: Mutant yeast highlights crucial CAG-reading protein
- HDBuzz: New analysis suggests 'small' CAG length doesn't matter at all
- hdbuzz-graeme-bilbe
- hd-buzz-gene-silencing
- HDBuzz Gray Area of HD
- HDBuzz Exosomoes
- HDBuzz Neutron Ray
- Sheep Brains and HD
- HDBuzz: Stem-cell neurons make the right connections
- HDBuzz: Closing the care gap new guidelines for HD care
- HDBuzz: What's the connection between Huntington's and cancer?
- HDBuzz: ASO gene silencing reaches further, lasts longer
- HDBuzz: Induced stemm cells make exciting advances
- Mapping the neighborhood: huntingtin's new protein partners
- HDBuzz: Does the HD Mutation affect Children's Growth
- HDBuzz Lithium with a twist gets second chance for HD
- HDBuzz: High-power brain scans reveal sodium changes in HD
- HDBuzz: Single Stranded RNA gene silencing
- CHDI Conference- Day 1
- CHDI Conference- Day 2
- HD Buzz on CHDI Conference- Day 3
- Hypothalmus
- HDBuzz: Illuminating Findings in Blood Cells
- Targeting oxidative stress in Huntington's Disease
- HDBuzz: Guard Dog Proteins
- HDBuzz: Dyeing to prevent dying?
- HDBuzz: Prominent HD researcher fabricated data
- HDBUZZ: Prana Biotech Publishes Animal Data
- HDBuzz: Gone fishing: protein network screen
- UNO has not discovered a cure for HD
- HDBuzz: HD and Sleep
- HDBuzz: N17 Region of Huntingtin
- HDBuzz: Liver changes in Huntington Patients
- HDBuzz: No Surprises in Published HART results
- HDBuzz: New Genetic Testing Technique
- HDBuzz: Rules for a good Sleep
- HDBuzz: Lost in translation?
- HDBuzz: Major Roche-Isis deal
- HDBuzz: Is Access to Genetic Testing a Problem?
- HDBuzz: Splicing with Danger
- HDBuzz: Landmark Study puts HD trials on TRACK
- HD Glossary
- Links to Other Research
- Past & Future
- HD Insights
- Reports Library
Prominent Huntington's disease researcher "fabricated data" in grant applications
By Dr Ed Wild on January 06, 2013
Edited by Dr Jeff Carroll
”The National Institute for Health’s Office for Research Integrity has ruled that noted Huntington’s disease researcher Dr Paul Muchowski, of the Gladstone Institutes at University of California, San Francisco, committed “research misconduct by falsifying and fabricating data” in several applications for funding. Muchowski has now resigned from his position with the Gladstone Institutes.
As the leader of a large Huntington’s disease research group, Muchowski has been linked with some of the most eye-catching research breakthroughs in recent years — including drug candidates for KMO inhibition and CB2 activation. His findings have featured in some of the top scientific journals and we’ve reported on them here at HDBuzz.
Muchowski’s applications for research funding were reviewed in detail by the Gladstone Institutes and the NIH. The investigation revealed four instances where work that was described as complete had in fact not been done, and one case where an image showing one type of brain cell was mislabelled as another type.
The NIH concluded that Muchowski had committed “research misconduct by falsifying and fabricating data”. Muchowski accepted the ruling and agreed to have his research supervised for two years, but the NIH has allowed him to keep his funding and apply for future grants.
So does this ruling mean that some Huntington’s disease research findings are now in question? The full facts of the case may not emerge for some time, but it’s reassuring that after two detailed investigations, nobody involved has yet called for the withdrawal of any of Muchowski’s published research, according to our sources.
Equally importantly, independent researchers working on the KMO and CB2 pathways, and other findings of Muchowski’s group, have carried out research that supports those published results. So — as far as we can tell on the basis of the information available right now — this development doesn’t mean we have to abandon those promising lines of enquiry.
We’re sorry to be kicking off our 2013 research news coverage with such a dark cloud, but take it from us, there’s sunnier news on the way.
Learn more
- Full ruling by the Office of Research Integrity of The National Institutes for Health
- San Francisco Chronicle article on this story
- Letter of apology from Paul Muchowski to the Huntington's Disease community
- Bone marrow transplantation in Huntington's Disease
- KMO inhibitor drug improves lifespan of Huntington's disease mice
- CHDI Report: Day 3